8/8/2019 40925 Deed 01

1/19

8/8/2019 40925 Deed 01

2/19

8/8/2019 40925 Deed 01

3/19

8/8/2019 40925 Deed 01

4/19

8/8/2019 40925 Deed 01

5/19

8/8/2019 40925 Deed 01

6/19

8/8/2019 40925 Deed 01

7/19

8/8/2019 40925 Deed 01

8/19

8/8/2019 40925 Deed 01

9/19

8/8/2019 40925 Deed 01

10/19

10

Performance HighlightsPerformance Highlights

Consolidated: FHL and Subsidiaries

Network: FHL, Subsidiaries, Associates and O&M Hospitals

8/8/2019 40925 Deed 01

11/19

0

50

100

150

200

250

300

Consolidated Network

161

189

232

299 Q3FY09 Q3FY10

11

Q3 FY 10 Consolidated

Operating Revenue - Rs. 232.5 Cr 44%

Operating EBITDA - Rs. 35.6 Cr 43%Net Profit - Rs. 21.7 Cr 330%

Q3FY10 - Network Revenue - Rs. 299.1 Cr. 59%

9M FY10 Consolidated

Operating Revenue - Rs. 608.4 Cr. 33%

Operating EBITDA - Rs. 93.5 Cr. 56%

Net Profit - Rs. 42.3 Cr. 330%

9M FY10 - Network Revenue - Rs. 808.2 Cr. 49%

SnapshotSnapshot Financial PerformanceFinancial PerformanceRs. in Cr.

Statutory Q3FY09 Q3FY10

Occupancy 70% 74%

ARPOB (Annualized - Rs. Lakhs) 75 86

ALOS (Days) 3.9 3.7

+44%

+59%

Operating Revenues

8/8/2019 40925 Deed 01

12/19

Operating Revenue and PATOperating Revenue and PAT

12

161.1172.6

185.4 190.5

232.5

13.0

21.7

7.6

6.2

5.1

0.0

50.0

100.0

150.0

200.0

250.0

Q3FY09 Q4FY09 Q1FY10 Q2FY10 Q3FY10

0.0

5.0

10.0

15.0

20.0

25.0

Operating Revenues PAT

Rs. in Cr.

Revenues

44%

PAT 330%

*PAT above is excluding exceptional items of gain of Rs. 6. 2 Cr. in Q2FY09 and our share of loss of Rs. 1.4 Cr in Malar hospital in Q4FY09

Consecutive positive returns

8/8/2019 40925 Deed 01

13/19

SummarySummary Consolidated Profit and LossConsolidated Profit and Loss Q3 FY10Q3 FY10

Particulars Q3 FY10(Rs. Cr.)

% Q3 FY09(Rs. Cr.)

% Q-o-QGrowth

Operating Revenue 232.5 100.0% 161.1 100.0% 44.3%

Other Income # 8.7 3.7% 5.8 3.6% 50.8%

Total Income 241.2 166.8 44.6%

Direct Costs 64.3 27.7% 46.3 28.7% 39.0%

Employee Costs 48.2 20.7% 39.1 24.3% 23.3%

Other Costs 84.4 36.3% 50.8 31.6% 66.0%

EBITDA 44.3 19.0% 30.6 19.0% 44.5%

Finance Costs 6.9 3.0% 11.2 7.0% -38.8%

Depreciation & Amortization 13.8 5.9% 11.9 7.4% 16.2%

PAT 21.7 9.4% 5.1 3.1% 329.6%

EPS for the quarter (Rs.) 0.88 0.22

13

#Other income includes interest income and miscellaneous income

8/8/2019 40925 Deed 01

14/19

SummarySummary Consolidated Profit and LossConsolidated Profit and Loss 9MFY109MFY10

14

Particulars9MFY10(Rs. Cr.) (%)

9MFY09(Rs. Cr.) (%) Growth (%)

Operating Revenue 608.4 100.0% 457.9 100.0% 32.9%

Other Income # 15.4 2.5% 23.9 5.2% -35.7%

Total Income 623.8 481.9 29.5%

Direct Costs 171.9 28.2% 134.6 29.4% 27.7%

Employee Costs 132.7 21.8% 112.1 24.5% 18.4%

Other Costs 210.3 34.6% 151.6 33.1% 38.8%

EBITDA 108.9 17.9% 83.7 18.3% 30.1%

Finance Costs 25.0 4.1% 34.3 7.5% -27.0%

Depreciation & Amortization 36.9 6.1% 35.9 7.8% 2.8%

PAT* 42.3 6.9% 9.8 2.1% 330.2%

EPS for the period 1.70 0.71

#Other income includes interest income and miscellaneous income* PAT is arrived after excluding exceptional items

8/8/2019 40925 Deed 01

15/19

15

Hospital PerformancesHospital Performances

15

8/8/2019 40925 Deed 01

16/19

8/8/2019 40925 Deed 01

17/19

Cardiac, 43%

Ortho, 8%

Neuro, 5%

Onco, 2%

Renal, 4% Gastro, 2%

MSH, 17%

OPD, 10%

Pulmo, 2%

Gynae, 3%

Others, 4%

Other, 19%

Specialty MixSpecialty Mix 9MFY109MFY10

17

Focus on key specialties Cardiac, Neuro, Ortho, Renal & Onco to continue

8/8/2019 40925 Deed 01

18/19

8/8/2019 40925 Deed 01

19/19

Thank YouThank You

19